# Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney Disease

> **NCT06160622** · PHASE1 · COMPLETED · sponsor: **Guangdong Raynovent Biotech Co., Ltd** · enrollment: 16 (actual)

## Conditions studied

- Kidney Impairment

## Interventions

- **DRUG:** Leritrelvir

## Key facts

- **NCT ID:** NCT06160622
- **Lead sponsor:** Guangdong Raynovent Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-26
- **Primary completion:** 2023-12-12
- **Final completion:** 2023-12-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06160622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06160622, "Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06160622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*